Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.
2.

Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.

Tortella BJ, Alvir J, McDonald M, Spurden D, Fogarty PF, Chhabra A, Pleil AM.

J Manag Care Spec Pharm. 2018 Jul;24(7):643-653. doi: 10.18553/jmcp.2018.17212. Epub 2018 Jan 24.

3.

Prevalence of and risk factors for cerebral microbleeds among adult patients with haemophilia A or B.

Husseinzadeh H, Chiasakul T, Gimotty PA, Pukenas B, Wolf R, Kelty M, Chiang E, Fogarty PF, Cuker A.

Haemophilia. 2018 Mar;24(2):271-277. doi: 10.1111/hae.13398. Epub 2017 Dec 28.

PMID:
29282815
4.

Publish, perish, or put patients first?

Fogarty PP.

Int J Gynaecol Obstet. 2018 Feb;140(2):135-136. doi: 10.1002/ijgo.12383. Epub 2017 Nov 26. No abstract available.

PMID:
29178329
5.

Revascularization strategies and in-hospital management in acute coronary syndromes complicated by hemophilia A or hemophilia B.

Reilley MJ, Blair A, Matthai WH, Vega R, Buckley M, Gimotty PA, Fogarty PF.

Blood Coagul Fibrinolysis. 2017 Dec;28(8):650-657. doi: 10.1097/MBC.0000000000000655.

PMID:
28763308
6.

Recombinant factor VIIa addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IXa/VIIIa defect to rescue fibrin generation.

Li R, Panckeri KA, Fogarty PF, Cuker A, Diamond SL.

Haemophilia. 2017 Sep;23(5):759-768. doi: 10.1111/hae.13259. Epub 2017 May 5.

7.

Interventional therapies and in-hospital outcomes in acute coronary syndromes complicated by von Willebrand disease.

Fogarty PF, Blair A, Vega R, Matthai WH, Gimotty PA.

Haemophilia. 2017 May;23(3):400-407. doi: 10.1111/hae.13149. Epub 2016 Dec 14.

PMID:
27976460
8.

Pilot randomized, non-inferiority, cross-over trial of once-weekly vs. three times-weekly recombinant factor VIII prophylaxis in adults with severe haemophilia A.

Ragni MV, Yabes JG, Fogarty PF, Josephson NC, Kessler CM, Neff AT, Raffini L, Brummel-Ziedins K, Moore CG.

Haemophilia. 2017 Jan;23(1):e43-e46. doi: 10.1111/hae.13131. Epub 2016 Dec 11. No abstract available.

9.

Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study.

James PD, Mahlangu J, Bidlingmaier C, Mingot-Castellano ME, Chitlur M, Fogarty PF, Cuker A, Mancuso ME, Holme PA, Grabell J, Satkunam N, Hopman WM, Mathew P; Global Emerging HEmostasis Experts PanelĀ (GEHEP).

Haemophilia. 2016 Nov;22(6):912-918. doi: 10.1111/hae.13089.

PMID:
27868369
10.

Gene therapy for hemophilia: past, present and future.

George LA, Fogarty PF.

Semin Hematol. 2016 Jan;53(1):46-54. doi: 10.1053/j.seminhematol.2015.10.002. Epub 2015 Oct 28. Review.

PMID:
26805907
11.

Hemophilia in the 21st century: tremendous progress, tremendous opportunity.

Fogarty PF.

Semin Hematol. 2016 Jan;53(1):1-2. doi: 10.1053/j.seminhematol.2015.10.007. Epub 2015 Oct 26. No abstract available.

PMID:
26805900
12.

Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey.

Fogarty PF, Mancuso ME, Kasthuri R, Bidlingmaier C, Chitlur M, Gomez K, Holme PA, James P, Kruse-Jarres R, Mahlangu J, Mingot-Castellano ME, Soni A; Global Emerging Hemophilia Panel (GEHEP).

Haemophilia. 2015 Sep;21(5):589-97. doi: 10.1111/hae.12652. Epub 2015 Feb 17.

PMID:
25689278
13.

Recombinant factor VIIa enhances platelet deposition from flowing haemophilic blood but requires the contact pathway to promote fibrin deposition.

Li R, Panckeri KA, Fogarty PF, Diamond SL.

Haemophilia. 2015 Mar;21(2):266-74. doi: 10.1111/hae.12558. Epub 2014 Oct 14.

PMID:
25311576
14.

Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.

Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, Pasi KJ, Hanabusa H, Pabinger I, Mahlangu J, Fogarty P, Lillicrap D, Kulke S, Potts J, Neelakantan S, Nestorov I, Li S, Dumont JA, Jiang H, Brennan A, Pierce GF.

J Thromb Haemost. 2014 Nov;12(11):1788-800. doi: 10.1111/jth.12723. Epub 2014 Oct 10.

15.

Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.

Tarantino MD, Fogarty PF, Shah P, Brainsky A.

Platelets. 2015;26(1):93-6. doi: 10.3109/09537104.2013.870333. Epub 2014 Jan 16.

PMID:
24433306
16.

Global Emerging HEmophilia Panel (GEHEP): A Multinational Collaboration for Advancing Hemophilia Research and Treatment.

James P, Kasthuri R, Kruse-Jarres R, Soni A, Kulkarni R, Bidlingmaier C, Chitlur M, Fogarty P, Gomez K, Holm PA, Mahlangu J, Mancuso ME, Mingot-Castellano ME, Dolan G.

Transfus Med Hemother. 2013 Oct;40(5):352-5. doi: 10.1159/000354843. Epub 2013 Aug 26. Review.

17.

Microfluidic assay of hemophilic blood clotting: distinct deficits in platelet and fibrin deposition at low factor levels.

Colace TV, Fogarty PF, Panckeri KA, Li R, Diamond SL.

J Thromb Haemost. 2014 Feb;12(2):147-58. doi: 10.1111/jth.12457.

18.

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P, Perry D, Shapiro A, Pasi KJ, Apte S, Nestorov I, Jiang H, Li S, Neelakantan S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Dodd N, Nugent K, Vigliani G, Luk A, Brennan A, Pierce GF; A-LONG Investigators.

Blood. 2014 Jan 16;123(3):317-25. doi: 10.1182/blood-2013-10-529974. Epub 2013 Nov 13.

19.

The impact of iodine supplementation and bread fortification on urinary iodine concentrations in a mildly iodine deficient population of pregnant women in South Australia.

Clifton VL, Hodyl NA, Fogarty PA, Torpy DJ, Roberts R, Nettelbeck T, Ma G, Hetzel B.

Nutr J. 2013 Mar 15;12:32. doi: 10.1186/1475-2891-12-32.

20.

Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia.

Tarantino MD, Fogarty P, Mayer B, Vasey SY, Brainsky A.

Blood Coagul Fibrinolysis. 2013 Apr;24(3):284-96. doi: 10.1097/MBC.0b013e32835fac99.

PMID:
23492914
21.

A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A.

Lane J, McLaren PJ, Dorrell L, Shianna KV, Stemke A, Pelak K, Moore S, Oldenburg J, Alvarez-Roman MT, Angelillo-Scherrer A, Boehlen F, Bolton-Maggs PH, Brand B, Brown D, Chiang E, Cid-Haro AR, Clotet B, Collins P, Colombo S, Dalmau J, Fogarty P, Giangrande P, Gringeri A, Iyer R, Katsarou O, Kempton C, Kuriakose P, Lin J, Makris M, Manco-Johnson M, Tsakiris DA, Martinez-Picado J, Mauser-Bunschoten E, Neff A, Oka S, Oyesiku L, Parra R, Peter-Salonen K, Powell J, Recht M, Shapiro A, Stine K, Talks K, Telenti A, Wilde J, Yee TT, Wolinsky SM, Martinson J, Hussain SK, Bream JH, Jacobson LP, Carrington M, Goedert JJ, Haynes BF, McMichael AJ, Goldstein DB, Fellay J; NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI).

Hum Mol Genet. 2013 May 1;22(9):1903-10. doi: 10.1093/hmg/ddt033. Epub 2013 Jan 30.

22.

Predicting patient dissatisfaction following laparoscopic Nissen fundoplication: an analysis of symptoms.

Beenen E, Fogarty P, Roberts RH.

Surg Endosc. 2013 May;27(5):1579-86. doi: 10.1007/s00464-012-2630-8. Epub 2012 Dec 12.

PMID:
23233010
23.

How we manage prostate biopsy and prostate cancer therapy in men with haemophilia.

Fogarty PF, Kouides P.

Haemophilia. 2012 May;18(3):e88-90. doi: 10.1111/j.1365-2516.2012.02787.x. Epub 2012 Apr 16.

PMID:
22500858
24.

ITP: tolerance lost.

Fogarty PF.

Blood. 2011 Dec 8;118(24):6232-4. doi: 10.1182/blood-2011-10-383893. No abstract available.

PMID:
22161847
25.
26.

Biological rationale for new drugs in the bleeding disorders pipeline.

Fogarty PF.

Hematology Am Soc Hematol Educ Program. 2011;2011:397-404. doi: 10.1182/asheducation-2011.1.397. Review.

PMID:
22160064
27.

An algorithmic approach to peripheral artery disease in hemophilia: extrapolation of management principles from noncoagulopathic patients.

Fogarty PF, Olin JW, Kessler CM, Konkle BA, Aledort LM.

Blood Coagul Fibrinolysis. 2012 Jan;23(1):23-9. doi: 10.1097/MBC.0b013e32834cb372.

PMID:
22143251
28.

Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia.

Fogarty PF, Tarantino MD, Brainsky A, Signorovitch J, Grotzinger KM.

Curr Med Res Opin. 2012 Jan;28(1):79-87. doi: 10.1185/03007995.2011.644849. Epub 2011 Dec 20.

PMID:
22117897
29.

Venous thromboembolic disease.

Streiff MB, Bockenstedt PL, Cataland SR, Chesney C, Eby C, Fanikos J, Fogarty PF, Gao S, Garcia-Aguilar J, Goldhaber SZ, Hassoun H, Hendrie P, Holmstrom B, Jones KA, Kuderer N, Lee JT, Millenson MM, Neff AT, Ortel TL, Smith JL, Yee GC, Zakarija A.

J Natl Compr Canc Netw. 2011 Jul 1;9(7):714-77. No abstract available.

30.

Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres.

Ragni MV, Fogarty PJ, Josephson NC, Neff AT, Raffini LJ, Kessler CM.

Haemophilia. 2012 Jan;18(1):63-8. doi: 10.1111/j.1365-2516.2011.02554.x. Epub 2011 May 4.

PMID:
21539695
31.

Outcomes in total elbow arthroplasty in patients with haemophilia at the University of California, San Francisco: a retrospective review.

Marshall Brooks M, Tobase P, Karp S, Francis D, Fogarty PF.

Haemophilia. 2011 Jan;17(1):118-23. doi: 10.1111/j.1365-2516.2010.02373.x.

PMID:
20738412
32.

Comorbidities in patients with persistent or chronic immune thrombocytopenia.

Enger C, Bennett D, Forssen U, Fogarty PF, McAfee AT.

Int J Hematol. 2010 Sep;92(2):289-95. doi: 10.1007/s12185-010-0636-3. Epub 2010 Jul 24.

PMID:
20652840
33.

An important factor in preoperative screening.

Olson AP, Fogarty PF, Dhaliwal G.

J Hosp Med. 2010 May-Jun;5(5):E6-7. doi: 10.1002/jhm.595. No abstract available.

PMID:
20533584
34.

Human chorionic gonadotrophin for threatened miscarriage.

Devaseelan P, Fogarty PP, Regan L.

Cochrane Database Syst Rev. 2010 May 12;(5):CD007422. doi: 10.1002/14651858.CD007422.pub2. Review.

PMID:
20464754
35.

Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation.

Fogarty PF.

Hematol Oncol Clin North Am. 2009 Dec;23(6):1213-21. doi: 10.1016/j.hoc.2009.08.004. Review.

PMID:
19932429
36.

How do we treat: upper gastrointestinal bleeding in adults with haemophilia.

Kouides PA, Fogarty PF.

Haemophilia. 2010 Mar;16(2):360-2. doi: 10.1111/j.1365-2516.2009.02130.x. Epub 2009 Oct 29. No abstract available. Erratum in: Haemophilia.2010 Mar;16(2):413.

PMID:
19878336
37.

How we treat: patients with haemophilia undergoing screening colonoscopy.

Fogarty PF, Kouides P.

Haemophilia. 2010 Mar;16(2):363-5. doi: 10.1111/j.1365-2516.2009.02120.x. Epub 2009 Oct 21. No abstract available. Erratum in: Haemophilia. 2010 Mar;16(2):413.

PMID:
19845773
38.

Emerging clinical concerns in the ageing haemophilia patient.

Konkle BA, Kessler C, Aledort L, Andersen J, Fogarty P, Kouides P, Quon D, Ragni M, Zakarija A, Ewenstein B.

Haemophilia. 2009 Nov;15(6):1197-209. doi: 10.1111/j.1365-2516.2009.02066.x. Epub 2009 Jul 21. Review.

PMID:
19686466
39.

Portomesenteric venous thrombosis after laparoscopic surgery: a systematic literature review.

James AW, Rabl C, Westphalen AC, Fogarty PF, Posselt AM, Campos GM.

Arch Surg. 2009 Jun;144(6):520-6. doi: 10.1001/archsurg.2009.81. Review.

PMID:
19528384
40.

Superficial myofibroblastoma of the lower female genital tract: first case report of a pregnant patient.

Adams B, Fogarty P, McKenna M, McManus D.

J Obstet Gynaecol. 2008 Aug;28(6):657-8. doi: 10.1080/01443610802421668. No abstract available.

PMID:
19003678
41.

Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology.

Wagman LD, Baird MF, Bennett CL, Bockenstedt PL, Cataland SR, Fanikos J, Fogarty PF, Goldhaber SZ, Grover TS, Haire W, Hassoun H, Hutchinson S, Jahanzeb M, Lee J, Linenberger ML, Millenson MM, Ortel TL, Salem R, Smith JL, Streiff MB, Vedantham S; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2008 Sep;6(8):716-53. No abstract available.

PMID:
18926086
42.

IgM-lambda paraproteinemia with associated cutaneous lymphoplasmacytic infiltrate in a patient who meets diagnostic criteria for POEMS syndrome.

Colaco SM, Miller T, Ruben BS, Fogarty PF, Fox LP.

J Am Acad Dermatol. 2008 Apr;58(4):671-5. doi: 10.1016/j.jaad.2007.07.021.

PMID:
18342713
43.

Diagnosis and management of venous thromboembolism.

Minichiello T, Fogarty PF.

Med Clin North Am. 2008 Mar;92(2):443-65, x. doi: 10.1016/j.mcna.2007.12.001. Review.

PMID:
18298988
44.

The epidemiology of immune thrombocytopenic purpura.

Fogarty PF, Segal JB.

Curr Opin Hematol. 2007 Sep;14(5):515-9. Review.

PMID:
17934361
45.

What did the doctor say?

Rao M, Fogarty P.

J Obstet Gynaecol. 2007 Jul;27(5):479-80.

PMID:
17701794
46.

First-episode psychosis in the community in NSW: detection and service utilization.

Fogarty P, Sara G.

Acta Neuropsychiatr. 2006 Dec;18(6):287-8. doi: 10.1017/S0924270800031203. No abstract available.

PMID:
27397278
47.

Venous thromboembolic disease. Clinical practice guidelines in oncology.

Wagman LD, Baird MF, Bennett CL, Bockenstedt PL, Cataland SR, Fanikos J, Fogarty PF, Goldhaber SZ, Grover TS, Haire W, Hassoun H, Jahanzeb M, Leung LL, Linenberger ML, Millenson MM, Ortel TL, Salem R, Smith JL, Streiff MB; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Oct;4(9):838-69. No abstract available.

PMID:
17020664
48.

Anti-interleukin-2 receptor antibody (daclizumab) treatment of corticosteroid-refractory autoimmune thrombocytopenic purpura.

Fogarty PF, Seggewiss R, McCloskey DJ, Boss CA, Dunbar CE, Rick ME.

Haematologica. 2006 Feb;91(2):277-8.

49.

Resetting the immune system in immune thrombocytopenic purpura: immunoablative strategies.

Fogarty PF, Dunbar CE.

Clin Adv Hematol Oncol. 2003 Jun;1(6):365-71. Review.

PMID:
16235418
50.

Supplemental Content

Loading ...
Support Center